Key result
The trans-spliced SpCas9 system successfully cleaved the HBB gene in HEK-293T cells with an allele modification frequency of 17.8%, achieving approximately half the nuclease activity of wild-type SpCas9.
Why the study?
Does trans-spliced SpCas9 allow site-specific DNA cleavage in human cells compared to wild-type SpCas9?
Does trans-spliced SpCas9 allow site-specific DNA cleavage in human cells compared to wild-type SpCas9?
A trans-splicing Cas9 system enables compact expression cassettes suitable for AAV packaging, achieving ~35% of wild-type nuclease activity in HEK-293T cells, though efficacy varies by cell type.
Answers are grounded in this paper and cite their sources.
Trans-spliced SpCas9 enables HBB editing in cell lines; leaves open therapeutic utility pending primary cell and in vivo validation.
CRISPR/Cas9 systems have been used in a wide variety of biological studies; however, the large size of CRISPR/Cas9 presents challenges in packaging it within adeno-associated viruses (AAVs) for clinical applications. We identified a two-cassette system expressing pieces of the S. pyogenes Cas9 (SpCas9) protein which splice together in cellula to form a functional protein capable of site-specific DNA cleavage. With specific CRISPR guide strands, we demonstrated the efficacy of this system in cleaving the HBB and CCR5 genes in human HEK-293T cells as a single Cas9 and as a pair of Cas9 nickases. The trans-spliced SpCas9 (tsSpCas9) displayed ~35% of the nuclease activity compared with the wild-type SpCas9 (wtSpCas9) at standard transfection doses, but had substantially decreased activity at lower dosing levels. The greatly reduced open reading frame length of the tsSpCas9 relative to wtSpCas9 potentially allows for more complex and longer genetic elements to be packaged into an AAV vector including tissue-specific promoters, multiplexed guide RNA expression, and effector domain fusions to SpCas9. For unknown reasons, the tsSpCas9 system did not work in all cell types tested. The use of protein trans-splicing may help facilitate exciting new avenues of research and therapeutic applications through AAV-based delivery of CRISPR/Cas9 systems.
No takes yet. Share an insight, caveat, or question.
Fine et al. (2015) studied In vitro gene editing. Trans-splicing SpCas9 (tsSpCas9) vs. Wild-type SpCas9 (wtSpCas9) was evaluated on Allele modification frequency at the HBB locus. The trans-spliced SpCas9 system successfully cleaved the HBB gene in HEK-293T cells with an allele modification frequency of 17.8%, achieving approximately half the nuclease activity of wild-type SpCas9.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: